AU Real Estate Plans Rs 1200 Crore Housing Project in Ghaziabad UK Governments Proposed Food Price Caps Spark Industry Backlash Amid Broken System Concerns Milburn Welfare Spending on Youth Outpaces Job Investment Calls for Reform Soaring Egg Prices The Cost of UK Household Essentials Since 2022 Morgan Stanley Highlights Potential Turnaround for Franklin Resources BEN Australian Taxpayer Subsidies and BHP Climate Retreat Raise Questions on Emission Goals UMBF Q1 2026 Earnings Strong EPS Beat Drives Stock Rally BMY Q1 2026 Earnings Strong EPS Beat Amid Cautious Market Response ALGM Q1 2026 Earnings EPS Beats Estimates by Nearly 2 Amidst Revenue Uncertainty LEXX Q1 2026 Earnings Narrower Loss Surprises as Bioscience Firm Advances Drug Delivery Pipeline Acadia Healthcare Q1 2026 Earnings Strong EPS Surprise Amid Operational Focus Iveda Solutions IVDA Q2 2024 Earnings Narrower Loss Beats Expectations Despite Revenue Uncertainty Valvoline VVV Holds Steady Near Support as Modest Gains Fuel Cautious Optimism Gorilla Technology Group GRRR Surges 946 as Shares Test Key Resistance at 1877 AIRO Group Holdings AIRO Gains 243 as Bullish Momentum Builds Near Resistance Vroom Inc VRM Slides 518 to 119 Support Level Under Pressure Sunstone Hotel Investors SHO Rises Modestly Tests Key Resistance Near 1125 GlobalFoundries Establishes Dedicated Quantum Technology Unit Signaling Strategic Pivot in Semiconductor Landscape SBCF Q1 2026 Earnings EPS Beats Estimates Amid Stable Operations BlackBerry BB Surges 645 Key Levels and Potential Drivers VINP Q1 2026 Earnings EPS Misses Estimates Stock Declines SMR Q1 2026 Earnings EPS Miss Amid Continued PreRevenue Operations NU Q1 2026 Earnings EPS Misses Estimates Amid Strong Operational Momentum OPTU Q1 2026 Earnings A Staggering EPS Miss Rattles Investors CBL Q4 2024 Earnings Massive EPS Surprise Highlights Operational Resilience American Shared Hospital Services AMS Q1 2026 Earnings Significant EPS Miss Amid Operational Challenges Alaunos Therapeutics TCRT Q4 2023 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline